A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Ofatumumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Dec 2012 Planned End Date changed from 1 Mar 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 12 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.